Stockwatch: Specialty Pharma Falling
If this downbeat first-quarter earnings season has claimed a scalp, it is the business model of specialty pharmaceutical companies. Last week the analysts from Jefferies described the specialty pharmaceutical sector as being in freefall.
You may also be interested in...
After Papa's exit from Perrigo, the company is left to pick up the pieces and is not as strong a business as investors had previously thought.
Teva Pharmaceutical Industries is to acquire Allergan Generics in a transaction valued at $40.5bn. The news is the culmination of a weekend of rumors that the deal was in the offing. Teva said that as a result of the agreement, it is dropping its pursuit of Mylan. The origin of the majority of Allergan's generic pharmaceuticals is the company formerly known as Actavis.
Deals announced by Sanofi and Novartis at this year’s virtual J.P. Morgan Healthcare Conference and a smattering of full-year revenue preannouncements did not mark a bumper start to the year.